Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results
27 févr. 2023 07h30 HE
|
Zevra Therapeutics
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced...
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023
24 févr. 2023 07h30 HE
|
Zevra Therapeutics
Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick Disease Type C (NPC) CELEBRATION, Fla.,...
Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023
23 févr. 2023 07h30 HE
|
KemPharm
CELEBRATION, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced...
CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics
22 févr. 2023 08h50 HE
|
KemPharm
New name, Greek for “zebra,” is the internationally-recognized symbol for the rare disease community Branding reflects Company’s commitment to making rare disease therapies available through...
KemPharm Announces Corporate Name Change to Zevra Therapeutics
22 févr. 2023 07h30 HE
|
KemPharm
New name, Greek for “zebra,” is the internationally-recognized symbol for the rare disease community Branding reflects Company’s commitment to making rare disease therapies available through its...
KemPharm Enhances Senior Management Team
31 janv. 2023 07h30 HE
|
KemPharm
Daniel Gallo, Ph.D., Appointed Senior Vice President of Medical Affairs and Advocacy Abbi Maher, J.D., Named Vice President of Legal Affairs CELEBRATION, Fla., Jan. 31, 2023 (GLOBE NEWSWIRE) --...
KemPharm Issues Letter to Shareholders
24 janv. 2023 07h30 HE
|
KemPharm
CELEBRATION, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for...
KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy
18 janv. 2023 07h30 HE
|
KemPharm
CELEBRATION, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare...
KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer
11 janv. 2023 07h30 HE
|
KemPharm
Expanded roles for Guenther and Mickle support broader evolution into a leading rare disease company CELEBRATION, Fla., Jan. 11, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm,...
KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company
09 janv. 2023 06h30 HE
|
KemPharm
Matthew R. Plooster named Chairman of the Board of DirectorsRichard W. Pascoe appointed Chief Executive OfficerTravis C. Mickle, Ph.D. transitions to PresidentJoshua Schafer appointed Chief Commercial...